IMMUNOSUPPRESSION
Clinical trials for IMMUNOSUPPRESSION explained in plain language.
Never miss a new study
Get alerted when new IMMUNOSUPPRESSION trials appear
Sign up with your email to follow new studies for IMMUNOSUPPRESSION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Liver scan could free transplant patients from risky drugs
Disease control Recruiting nowThis study aims to see if a special ultrasound scan (FibroScan) can help doctors safely reduce the amount of strong anti-rejection drugs that liver transplant patients must take for life. These drugs prevent organ rejection but can cause serious long-term side effects like kidney…
Matched conditions: IMMUNOSUPPRESSION
Phase: NA • Sponsor: University of Alberta • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New hope for kids with Crohn's: testing drug combinations for Long-Term relief
Disease control Recruiting nowThis study is testing whether a drug called infliximab works better alone or when combined with other immunosuppressive medications to control Crohn's disease in children. It will involve 128 children aged 6-18 who have active Crohn's disease. The main goal is to see which approa…
Matched conditions: IMMUNOSUPPRESSION
Phase: PHASE4 • Sponsor: Children's Hospital of Fudan University • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Gene-Guided dosing aims to improve kidney transplant success
Disease control Recruiting nowThis study is testing whether checking a patient's genes before a kidney transplant can help doctors prescribe the correct starting dose of a crucial anti-rejection drug called tacrolimus. It will compare this genetic-guided approach to the current standard of care to see if it g…
Matched conditions: IMMUNOSUPPRESSION
Phase: PHASE4 • Sponsor: Instituto de Investigación Hospital Universitario La Paz • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
One pill a day? study tests simpler drug routine for liver transplant patients
Disease control Recruiting nowThis study is testing if taking all anti-rejection drugs once a day is as safe and effective as taking them twice a day for people who have received a liver transplant. The goal is to make the lifelong medication routine easier to follow, which could help patients stick to their …
Matched conditions: IMMUNOSUPPRESSION
Phase: PHASE4 • Sponsor: University Hospital, Limoges • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Medical first: robotic bladder transplant trial begins
Disease control Recruiting nowThis is the first-ever study to test transplanting a whole bladder from a deceased donor into a patient with end-stage bladder disease. The goal is to see if this robotic surgery is a feasible and better-tolerated alternative to current major surgeries that use a piece of bowel. …
Matched conditions: IMMUNOSUPPRESSION
Phase: NA • Sponsor: University of Southern California • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
Scientists probe link between immune defects and gum disease
Knowledge-focused Recruiting nowThis study aims to understand how genetic immune system problems affect oral health, particularly gum disease. Researchers will compare people with immune disorders, those with severe gum disease, and healthy volunteers by collecting samples like saliva, plaque, and blood. The go…
Matched conditions: IMMUNOSUPPRESSION
Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Scientists probe why trauma patients struggle with infections
Knowledge-focused Recruiting nowThis study aims to understand what happens to the immune system after severe injuries like car crashes or falls. Researchers will collect blood and bone marrow samples from 255 trauma patients and compare them to people having routine hip surgery. They want to learn why some inju…
Matched conditions: IMMUNOSUPPRESSION
Sponsor: University of Florida • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:41 UTC